These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18057310)

  • 21. Mineral and bone disorders in patients on dialysis: physiology and clinical consequences.
    McCarley PB; Arjomand M
    Nephrol Nurs J; 2008; 35(1):59-64. PubMed ID: 18372764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The need for better control of secondary hyperparathyroidism.
    Locatelli F
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V15-19. PubMed ID: 15284355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.). Introduction.
    Torregrosa JV; Bover J; Cannata Andía J
    Nefrologia; 2011; 31 Suppl 1():1-2. PubMed ID: 21468160
    [No Abstract]   [Full Text] [Related]  

  • 25. Chronic kidney disease-mineral and bone disorder: Guidelines for diagnosis, treatment, and management.
    Moschella C
    JAAPA; 2016 Jul; 29(7):21-9. PubMed ID: 27272731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Renal osteodystrophy--more than a mere bone disease].
    Saha H
    Duodecim; 2001; 117(21):2181-7. PubMed ID: 12184205
    [No Abstract]   [Full Text] [Related]  

  • 27. [Hyperparathyroidism in patients on long-term hemodialysis].
    Rodosskaia NK; Orlova II; Brazhnikova VV
    Klin Med (Mosk); 2009; 87(4):68-70. PubMed ID: 19514326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune, metabolic and epidemiological aspects of vitamin D in chronic kidney disease and transplant patients.
    Bacchetta J; Pelletier S; Jean G; Fouque D
    Clin Biochem; 2014 May; 47(7-8):509-15. PubMed ID: 24412344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperparathyroidism and bone disease after renal transplantation.
    Pavlović D; Orlić L
    Acta Med Croatica; 2002; 56(2):41-3. PubMed ID: 12596622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mineral metabolism disturbances in patients with chronic kidney disease.
    Kestenbaum B; Belozeroff V
    Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural course of secondary hyperparathyroidism after successful renal transplantation.
    Roof BS; Piel CF; Carpenter BJ; Gordan GS; Kountz S; Belzer F
    Proc Clin Dial Transplant Forum; 1971; 1():11-20. PubMed ID: 4951041
    [No Abstract]   [Full Text] [Related]  

  • 33. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism.
    Kazama JJ
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S44-7. PubMed ID: 17976085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bone and Nutrition. Nutrition care of renal osteodystrophy].
    Tanaka S; Ito M
    Clin Calcium; 2015 Jul; 25(7):1057-62. PubMed ID: 26119320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.).
    Torregrosa JV; Bover J; Cannata Andía J; Lorenzo V; de Francisco AL; Martínez I; Rodríguez Portillo M; Arenas L; González Parra E; Caravaca F; Martín-Malo A; Fernández Giráldez E; Torres A;
    Nefrologia; 2011; 31 Suppl 1():3-32. PubMed ID: 21468161
    [No Abstract]   [Full Text] [Related]  

  • 36. Impact of kidney bone disease and its management on survival of patients on dialysis.
    Lee GH; Benner D; Regidor DL; Kalantar-Zadeh K
    J Ren Nutr; 2007 Jan; 17(1):38-44. PubMed ID: 17198930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of mineral and bone disorders in chronic kidney disease.
    Matuszkiewicz-Rowińska J
    Pol Arch Med Wewn; 2010 Jul; 120(7-8):300-6. PubMed ID: 20693962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Physiopathology and therapy of renal osteodystrophy and secondary hyperparathyroidism].
    Fukagawa M
    Nihon Naika Gakkai Zasshi; 1999 Jul; 88(7):1245-50. PubMed ID: 10465972
    [No Abstract]   [Full Text] [Related]  

  • 39. [Vitamin D metabolism and chronic kidney insufficiency].
    Schaefer K; von Herrath D; Kraft D
    Dtsch Med Wochenschr; 1973 Jul; 98(27):1338-44. PubMed ID: 4351844
    [No Abstract]   [Full Text] [Related]  

  • 40. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.